{"database": "lobbying", "table": "lobbying_activities", "rows": [[1948853, "24e25b3f-6938-4788-be6d-38a3df976712", "Q1", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2017, "first_quarter", "MMM", "S. Con. Res. 3 - Budget Resolution for FY 2017 - Impact of reconciliation instructions on the prescription drug benefit and coverage for those covered through health care marketplaces and Medicaid beneficiaries. \n\nS. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. \n\nS. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2017-04-05T14:34:39.670000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1948853"], "units": {}, "query_ms": 0.4241210117470473, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}